Homepage
Author:
Zealand Pharma
Posted Date:
May 14, 2026
Zealand Pharma – Transactions related to share buy-back program (weeks 19-20, 2026)
Zealand Pharma
May 14, 2026
Zealand Pharma – Execution framework for share buy-back program
Zealand Pharma
May 7, 2026
Zealand Pharma Announces Financial Results for the First Three Months of 2026
Zealand Pharma
May 7, 2026
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
Zealand Pharma
May 7, 2026
The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting
Zealand Pharma
May 1, 2026
Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026
Zealand Pharma
May 1, 2026
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
Zealand Pharma
April 30, 2026
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Zealand Pharma
April 29, 2026
Zealand Pharma announces Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
Zealand Pharma
April 28, 2026
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma
April 22, 2026
1
2
3
Next
